Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals reports Q4 2025 revenue up 11.3% to $1.54B and 2026 guidance for mid‑$12B, driven by CF sales and new non‑CF orphan‑designated therapies.

Vertex Pharmaceuticals’ upcoming Q4 earnings, new orphan‑designated myasthenia gravis therapy and strategic autoimmune deals signal growth prospects and investor interest.

Vertex Pharmaceuticals sees institutional buying, analyst optimism and a WuXi Biologics deal that could diversify its biologics pipeline and drive future growth.

Vertex partners with WuXi Biologics to develop a trispecific T‑cell engager for B‑cell autoimmune diseases, aiming to broaden its portfolio beyond cystic fibrosis.

Vertex Pharmaceuticals sees investor interest rise as analysts upgrade CF pipeline, secure orphan drug status, and highlight strong safety‑efficacy data.

Vertex Pharmaceuticals’ latest R&D momentum, driven by Trikafta’s growth and oncology pipeline, sparks a bullish outlook—yet patent cliffs, rising R&D spend and regulatory pressures loom.

Vertex Pharmaceuticals readies its 44th J.P. Morgan Healthcare Conference presentation, spotlighting cystic fibrosis success, oncology progress, and new IBD & neurological data to boost investor confidence and revenue forecasts.

Vertex’s new pediatric gene‑editing data for sickle cell and beta‑thalassemia shows durable, safe results but triggered a 10% share drop amid concerns over small sample size, regulatory timing, and reimbursement hurdles.

Vertex’s new pediatric data confirm CASGEVY’s safety and efficacy, showing it works in children with sickle cell and thalassemia just as well as in adults.

Vertex’s povetacicept shows 48‑week proteinuria drops in IgAN and PMN—could be a game‑changer for kidney disease therapy and investor returns.